Endpoint Management Software for PASCAL Laser
  • Description
  • Endpoint Management utilizes advanced algorithms to control both power and exposure time of the laser. Using initial settings determined during titration, the system will guide laser output to deliver controlled, repeatable dose within therapeutic boundaries.

    Landmark Patterns give an added level of support by "landmarking" the periphery of the applied pattern. When setting to a sub-visible level, Landmark gives feedback on treatment dose, location and uptake in the retina.

     

  • Key Features
    • Fine control of laser output to deliver visible and non-visible laser applications.
    • Ability to titrate to the desired level with low-dose laser application.
    • Available as an upgrade to existing PASCAL Streamline™ and Streamline 577™, and Synthesis™ laser systems.
  • Brochures
  • Articles & Publications
  • Title: The Subthreshold Laser’s Role in Retinal Vascular Disease
    Author(s): Dr. Netan Choudhry, MD
    Publisher: Modern Retina from Ophthalmology Times
    Type: Trade Publication
    Release Date: October 18, 2018
    Summary:

    A novel subthreshold laser provides seamless adjunctive therapy that can supplement or obviate the need for future injections in certain retinal conditions.

    Title: PASCAL Endpoint Management: Subthreshold Laser Therapy for Macular Diseases
    Author(s): Victor H. Gonzalez, MD, & Francisco J. Rodriguez, MD
    Publisher: Retina Today
    Type: Trade Publication
    Release Date: September 1, 2017
    Summary:

    Approaches with and without anti-VEGF: How we choose to treat our patients.

    Title: Nondamaging Retinal Laser Therapy: Rationale and Applications to the Macula
    Author(s): Daniel Lavinsky, Jenny Wang, Philip Huie, Roopa Dalal, Seung Jun Lee, Dae Yeong Lee and Daniel Palanker
    Publisher: Investigative Ophthalmology & Visual Science
    Type: Trade Journal - Peer Reviewed
    Release Date: May 19, 2016
    Summary:

    Retinal photocoagulation and nondamaging laser therapy are used for treatment of macular disorders, without understanding of the response mechanism and with no rationale for dosimetry. To establish a proper titration algorithm, we measured the range of tissue response and damage threshold. We then evaluated safety and efficacy of nondamaging retinal therapy (NRT) based on this algorithm for chronic central serous chorioretinopathy (CSCR) and macular telangiectasia (MacTel).

    Title: Case studies: Laser therapy, injection paradigms for treatment of DME
    Author(s): Manish Nagpal, MD
    Publisher: Ophthalmology Times
    Type: Trade Publication
    Release Date: November 1, 2014
    Summary:

    When treating diabetic macular edema (DME), ophthalmologists often face the choice of which treatments should be used—either alone or in combination—that best prevent further damage to the retina, correct vision loss, and prevent eventual blindness.

    Dr. Manish Nagpal discusses patient cases and the use of combination therapy with Endpoint Management and PASCAL.

    Title: Endpoint Management Patient Case Study
    Author(s): Dr. Daniel Lavinsky
    Publisher: Topcon Medical Systems
    Type: White Paper
    Release Date: July 1, 2014
    Summary:

    This article describes Dr. Daniel Lavinsky’s treatment of a 54-year-old with severe non-proliferative diabetic retinopathy with macular edema using the PASCAL Streamline (577nm) Laser System.

    Title: Clinical Advances of Swept-Source OCT and New Non-Damaging Laser Treatment
    Author(s): Andrew J. Tatham, FRCOphth, FEBO
    Publisher: Review of Ophthalmology
    Type: Trade Journal - Peer Reviewed
    Release Date: March 1, 2014
    Summary:

    Three leading surgeons offer their insight and experience on imaging with optical coherence tomography as well as laser treatment options.

    Title: Laser Therapy a Novel Approach to DME, CSR.
    Author(s): Daniel Lavinsky, MD
    Publisher: Ophthalmology Times
    Type: Trade Publication
    Release Date: March 1, 2014
    Summary:

    An ophthalmologist with a practice in Brazil explains how using photothermal stimulation with an algorithm is an effective treatment for his patients with diabetic macular edema and central serous chorioretinopathy.

    Title: New Possibilities for Photo-Thermal Laser Treatment of Macular Disease: Endpoint Management with PASCAL
    Author(s): Dr. Yuichiro Ogura, Dr. Miho Nozaki, and Dr. Kishiko Ohkoshi
    Publisher: Topcon Medical Systems
    Type: White Paper
    Release Date: November 1, 2013
    Summary:

    A review of the content presented at the 36th Annual Meeting of the Japanese Society of Ophthalmic Surgeons – Luncheon Seminar 3, focusing on the application of Topcon’s PASCAL Laser System with Endpoint Management for the treatment of macular disease.

    Title: Software that Removes the Laser Guesswork
    Author(s): Rene Luthe, Senior Associate Editor
    Publisher: Retinal Physician
    Type: Trade Journal - Peer Reviewed
    Release Date: September 2, 2013
    Summary:

    Topcon’s Endpoint Management software with Landmark Patterns eliminates the retinal surgeon’s photocoagulation conundrum of either being able to see the treatment by creating a burn that causes collateral damage to the surrounding tissues, or decreasing the laser power to avoid collateral damage.

    Title: Subthreshold Retinal Treatment with Yellow 577-nm PASCAL Laser
    Author(s): Paulo Stanga, MD
    Publisher: Retina Today
    Type: Trade Publication
    Release Date: January 1, 2013
    Summary:

    There is evidence that barely visible laser photocoagulation can work within the macula as primary therapy for DME. Endpoint Management allows more accurate titration of the energy within the subthreshold range, creating the potential for significant reduction in collateral damage and allowing a good tissue healing response.

  • Images
  • Videos
  • Topcon EndPoint Management 2014
    Endpoint Management
    Topcon PASCAL Family of Products
    Topcon EndPoint Management 2014